ArticleBMC health services research2026
Greener active pharmaceutical ingredients: perspectives of European healthcare professionals.
Article in BMC health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical residues resulting from patient excretion, incorrect disposal and manufacturing of medicines contribute to environmental pollution and related risks. Designing active pharmaceutical ingredients of inherently lower environmental risk ('greener APIs') is one potential solution to this issue. To assess the current level of preparedness to adopt potentially greener APIs as a part of more sustainable medical care, the perspectives of healthcare professionals on greener APIs were evaluated by investigating related opportunities, barriers and the needs to overcome these barriers. Semi-structured interviews were conducted with professionals working in the healthcare sector in European countries between February and April 2024 (n = 16). The interviewees included doctors (3), pharmacists (3), experts in procurement (3), reimbursement (1), market authorisation (2), healthcare provision (2) and industry's sustainability reporting (1), as well as a professional working for an environmental NGO (1). Data was evaluated using qualitative content analysis. Interviewees' answers showed that some strategies already exist to account for environmental aspects in decision-making, e.g. by adding environmental criteria to the tenders of procurement agencies. Criteria on environmental properties of APIs can be expected to play a more significant role in the decision-making of HC professionals in future. Balancing molecular properties related to patient benefit and risk against environmental properties could be product specific. Frequently expressed needs to enable this include: access to reliable scientific data and evidence of environmental impacts of APIs, legislative and regulatory frameworks and guidance to ensure environmental properties are assessed and weighed in a centralised and harmonised manner. The evident interest among HC professionals to consider environmental properties in their decision-making may stimulate data sharing by pharmaceutical companies in the short-term and efforts to design greener APIs in the long-term. The marketing authorisation process is viewed as the main intervention point in the life cycle of pharmaceuticals to strengthen considerations of environmental risks. The authors conclude that future research should target the identified barriers and their solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.